CRM-197 Product Introduction
CRM-197 carrier protein is prepared by recombinant E. coli fermentation, it is a non-toxic single amino acid mutant of diphtheria toxin, with molecular weight comparable to diphtheria toxin, no formaldehyde detoxification, better protection of T-cell helper epitopes, and it is a safer and more effective carrier protein than diphtheria toxin.
It is safer and more effective carrier protein than diphtheria toxoid, due to its non-toxicity, single component, no need of formaldehyde and other chemicals detoxification treatment, so its purity is higher, which can reach more than 90%. Stronger binding properties, it can bind to various molecules and membranes, is not affected by temperature and pH, and always maintains its three-dimensional structure during processing. The lysine residues are more exposed on the molecule and can be used to mediate polysaccharide attachment by a junction molecule. It can be piggybacked with other small molecules, such as polysaccharides, oligosaccharides, peptides and other substances, to prepare conjugate vaccines against a variety of infectious diseases.
Currently, CRM-197 has been successfully applied to Hib polysaccharide conjugate vaccine, 7-valent and 13-valent pneumonia polysaccharide conjugate vaccines, and monovalent or multivalent polysaccharide conjugate vaccines of groups A, C, Y, and W135 have also been approved for use in the United States, Europe, Canada, and China. CRM-197-based pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib) and quadrivalent (diphtheria, tetanus, pertussis and Hib) vaccines have also been successfully marketed and approved. CRM-197 can also be used in the development of vaccines against various bacterial infectious diseases such as tuberculosis, typhoid fever, group A streptococcus and nosocomial infections.
CRM-197 can also be involved in cancer treatment, as it can inhibit the growth and reproduction of cancer cells. Studies have shown that CRM-197 inhibits tumor formation by binding to the soluble form of epidermal growth factor HB-EGF and its precursors, preventing its activation of the ErbB receptor to interrupt protein synthesis and impede mitosis.CRM-197 can work synergistically with paclitaxel to inhibit the development of ovarian cancer; it can also be used as a chemosensitizing agent to potentiate the cytotoxicity of gemcitabine in human glioma cells; and it can also help the drug to pass through the bloodstream. toxicity; it can also help the drug to cross the blood-brain barrier and treat brain tumors. In addition, CRM-197 is more often used as a cancer vaccine carrier and participates in cancer immunotherapy, playing an important role in the treatment and prevention of numerous cancers, such as glioma, pancreatic cancer, oral cancer, leukemia, triple-negative breast cancer, and adrenocortical cancer.
Product Information:
Product Name: CRM-197 carrier protein
Product Code: GC05003
Grade: GLP grade, GMP grade
Package specification: 5mg/vial, 100mg/vial (customization available)